GA_P advises in Sanitas’s investment in MIMO Biosciences

Gómez-Acebo & Pombo has advised Sanitas in its investment in MIMO Biosciences (Modelling Immunotherapy In Oncology), spin-off of CIMA University of Navarra.

Sanitas, a company specializing in health care, joins forces with two private investors in the field of research and enters as a shareholder in the MIMO Biosciences project, a spin-off company arising from the research results obtained at CIMA University of Navarra, focused on cancer immunotherapy, during the last twelve years. Its mission is to provide preclinical research services based on unique models that recapitulate a wide range of genetic alterations of different hematological malignancies, including multiple myeloma and lymphomas.

This is a framework agreement for health research, in the first phase of which new models will be developed to accelerate the development of immunotherapy drugs for different types of hematological cancers.

The Gómez-Acebo & Pombo team was formed by; Álvaro Mateo, Patricia Pérez and Rodrigo Fernández-Chillón, partner and associates of the corporate practice; Borja Carvajal and Irene Fernández Puyol, partners of public and regulated sectors; Luis Cuesta and Pablo Soler, associates of tax; Silvia Muñoz, associate of intellectual property and Borja González Elejabarrieta, Natalia Mestres, associate of labor and employment.